1. Harris N, Jaffe E, Diebold J, et al.: World Health Organization Classification of neoplastic diseases of the hematopoeitic and lymphoid tissues: report of the clinical advisory committee meeting—Airlie House, Virgina, November 1997. J Clin Oncol 17:3835-3849, 1999.

2. Hansmann ML, Stein H, Dallenbach F, Fellbaum C:

Diffuse lymphocyte-predominant Hodgkin's disease

(diffuse paragranuloma). A variant of the B-cell-derived nodular type. Am J Pathol 138:29-36, 1991.

3. Lukes R, Butler J, Hicks E: Natural history of Hodgkin's disease as related to its pathologic picture. Cancer 19:317-344, 1966.

4. Colby TV, Hoppe RT, Warnke R: Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer 49:1848-1858, 1981.

5. Diehl V, Sextro M, Franklin J, et al.: Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease. J Clin Oncol 17:776-783, 1999.

6. Bodis S, Kraus MD, Pinkus G, et al.: Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 15:3060-3066, 1997.

7. Franklin J, Tesch H, Hansmann ML, Diehl V: Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. Ann Oncol 9(suppl 5):S39-S44, 1998.

8. Pappa VI, Norton AJ, Gupta RK, Wilson AM, Rohatiner AZ, Lister TA: Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol 6:559-565, 1995.

9. Russell KJ, Hoppe RT, Colby TV, Burns BF, Cox RS,

Kaplan HS: Lymphocyte predominant Hodgkin's disease: clinical presentation and results of treatment. Radiother Oncol 1:197-205, 1984.

10. MacMahon B: Epidemiological evidence on the nature of Hodgkin's disease. Cancer 10:1045-1054, 1957.

11. Leibenhaut M, Hoppe RT, Varghese A, Rosenberg S: Subdiaphragmatic Hodgkin's disease: laparotomy and treatment results in 49 patients. J Clin Oncol 5: 1050-1055, 1987.

12. Rosenberg SA, Kaplan HS: Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Res 26:1225-1231, 1966.

13. Stein H, Delsol G, Pileri S, et al.: Classical Hodgkin lymphoma. In: Jaffe E, Harris N, Stein H, Vardiman J (eds.) World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 244-253.

14. Spyridonidis A, Fischer K, Glocker F, Fetscher S, Klisch J, Behringer D: Paraneoplastic cerebellar degeneration and nephrotic syndrome preceding Hodgkin's disease: case report and review of the literature. Eur J Haematol 68: 318-321, 2002.

15. Emir S, Kutluk M, Gogus S, Buyukpamukeu M: Paraneoplastic cerebellar degeneration and Horner syndrome: association of two uncommon findings in a child with Hodgkin disease. JPediatr Hematol Oncol 22: 158-161, 2000.

16. Smitt P, Kinoshita A, De Leeuw B, et al.: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342:21-27, 2000.

17. Martinelli G, Zinzani P, Magagnoli M, Vianelli N, Tura S: Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin's disease in complete hematological remission. Haematologica 83:669-670, 1998.

18. Xiros N, Binder T, Anger B, Bohlke J, Heimpel H: Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin's disease. Eur J Haematol 40:437-441, 1998.

19. Dourakis S, Tzemanakis E, Deutsch M, Kafiri G, Hadziyannis S: Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol 11:1055-1058, 1999.

20. Nadiminti Y, Wang JC, Chou SY, Pineles E, Tobin MS: Lactic acidosis associated with Hodgkin's disease: response to chemotherapy. N Engl J Med 303:15-17, 1980.

21. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998.

22. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM: Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) 225-247, 2003.

23. Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V: Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. J Clin Oncol 13:403-409, 1995.

24. Bartl R, Frisch B, Burkhardt R, Huhn D, Pappenberger R: Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. Br J Haematol 51:345-360, 1982.

25. Horning SJ, Hoppe RT, Breslin S, Bartlett N, Brown W, Rosenberg S: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002.

26. Hudson MM, Greenwald C, Thompson E, et al.: Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 11:100-108, 1993.

27. Aleman B, van den Belt-Dusebout A, Klokman W, van't Veer M, Bartelink H, van Leeuwen F: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003.

28. Ng A, Bernardo M, Weller E, et al.: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100:1989-1996, 2002.

29. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971.

30. Lister TA, Crowther D, Sutcliffe SB, et al.: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989.

31. Leibenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA: Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 7:81-91, 1989.

32. Mauch P, Larson D, Osteen R, et al.: Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 8:257-265, 1990.

33. Zinzani PL, Zompatori M, Bendandi M, et al.: Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 22:131-135, 1996.

34. Front D, Israel O: The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 25:60-71, 1995.

35. Abrahamsen AF, Lien HH, Aas M, et al.: Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study. Ann Oncol 5:433-436, 1994.

36. King SC, Reiman RJ, Prosnitz LR: Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol 12:306-311, 1994.

37. Salloum E, Brandt DS, Caride VJ, et al.: Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol 15:518-527, 1997.

38. Young CS, Young BL, Smith SM: Staging Hodgkin's disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging 1:161-164, 1998.

39. Delbeke D, Martin WH, Morgan DS, et al.: 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol 4:105-114, 2002.

40. Jerusalem G, Beguin Y, Fassotte MF, et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglu-cose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999.

41. Guay C, Lepine M, Verreault J, Benard F: Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 44:1225-1231, 2003.

42. Peylan-Ramu N, Haddy TB, Jones E, Horvath K, Adde MA, Magrath IT: High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 7:1800-1806, 1989.

43. Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J: False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 38:888-890, 1997.

44. Anagnostopoulos I, Hansmann ML, Franssila K, et al.: European Task Force on lymphoma project on lymphocyte predominance Hodgkin's disease: histologic and immunohistologic analysis of submitted cases reveals

2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889, 2000.

45. Stein H, Delsol G, Pileri S, et al.: Nodular lymphocyte predominant Hodgkin lymphoma. In: Jaffe E, Harris N, Stein H, Vardiman J (eds.) World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:240-243.

46. Miettinen M, Franssila K, Saxen E: Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphoma. Cancer 51: 2293-2300, 1993.

47. Hansmann ML, Stein H, Fellbaum C, Hui P, Parwaresch M, Lennert K: Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol 20:1169-1175, 1989.

48. Greiner TC, Gascoyne RD, Anderson ME, et al.: Nodular lymphocyte-predominant Hodgkin's disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 87: 4302-4310, 1996.

0 0

Post a comment